NNRTI

Edurant (rilpivirine) is a once daily non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of human immunodeficiency virus (HIV-1) infection in combination with other antiretroviral agents in antiretroviral treatment-naive patients 12 years of age and older and weighing at least 35-kg with a viral load <= 100,000 HIV RNA copies/mL.

Olgularin %49.5'i INI, %8.2'si NNRTI ve %42.3'u PI temelli ART rejimi kullanmistir (Tablo 1).

Data on the use of boosted PIs together with an NNRTI are less promising.

Of these, 2 had nucleoside reverse transcriptase inhibitor (NRTI) resistance, 2 had NNRTI resistance, 7 had both NNRTI and NRTI resistance and 2 had both PI and NRTI resistance.

Olgularin 46'sina PI, 44'une INSTI ve besine NNRTI bazli kombinasyonlar baslandi.

These include exposure to nevirapine or efavirenz for PMTCT, with expected universal selection of NNRTI mutations in the exposed, and even modest rates of RMs in the unexposed (a reported rate of 24% in a PMTCT-unexposed population in South Africa (SA)).

The observed numbers of RAMs against PI, NRTI and NNRTI are listed in Table 2.

[9] The World Health Organization (WHO, 2010 revision) guidelines recommend initiation of antiretroviral therapy with two NRTI (zidovudine or tenofovir disoproxil fumarate with lamivudine [3TC] or emtricitabine [FTC) and a NNRTI (efavirenz [EFV] or nevirapine).

Depending on age, availability and as per WHO recommendations at the time of diagnosis, a combination of the two NRTIs (ZDV and 3TC) plus either NNRTI (nevaripine) or the PI (nelfinavir) was used to initiate therapy.

Predictor variables were sociodemographic characteristics (age at ART start, sex, marital status, city of residence, and occupation category); factors related to health care system utilization (referral center of attendance, mean number of medical visits per year, time between HIV diagnosis and ART initiation, and registration of hospitalization); clinical and laboratory data (T-CD4+ lymphocyte count and viral load at ART start and recording of AIDS-defining illness before first ART prescription); and first ART regimen, classified into two categories: combination of two nucleoside transcriptase inhibitors (NRTIs) and a nonnucleoside transcriptase inhibitor (NNRTI) and two NRTIs and a ritonavir- (RTV-) boosted or unboosted protease inhibitor (PI).